Axim Biotechnologies Depreciation & Amortization Growth & History (AXIM)
Axim Biotechnologies's depreciation and amortization was $432,394 for fiscal 2024.
View full Axim Biotechnologies company overviewAxim Biotechnologies annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $432,394 | $5,375 | +1.26% |
| 2023 | 2023-12-31 | $427,019 | $893 | +0.21% |
| 2022 | 2022-12-31 | $426,126 | −$1.7M | −79.86% |
| 2021 | 2021-12-31 | $2.1M | $2.1M | +13122.22% |
| 2020 | 2020-12-31 | $16,001 | $9,487 | +145.64% |
| 2019 | 2019-12-31 | $6,514 | −$6,317 | −49.23% |
| 2018 | 2018-12-31 | $12,831 | $9,475 | +282.33% |
| 2017 | 2017-12-31 | $3,356 | $0 | 0.00% |
| 2016 | 2016-12-31 | $3,356 | $2,237 | +199.91% |
| 2015 | 2015-12-31 | $1,119 | $1,119 | — |
| 2014 | 2014-12-31 | $0 | — | — |
Axim Biotechnologies quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | $108,130 | $1 | +0.00% |
| Q1 2025 | 2025-03-31 | $108,130 | $123 | +0.11% |
| Q2 2024 | 2024-06-30 | $108,129 | $1,374 | +1.29% |
| Q1 2024 | 2024-03-31 | $108,007 | $1,252 | +1.17% |
| Q3 2023 | 2023-09-30 | $106,755 | $11 | +0.01% |
| Q2 2023 | 2023-06-30 | $106,755 | $741 | +0.70% |
| Q1 2023 | 2023-03-31 | $106,755 | $228 | +0.21% |
| Q3 2022 | 2022-09-30 | $106,744 | $99,809 | +1439.21% |
| Q2 2022 | 2022-06-30 | $106,014 | $99,180 | +1451.27% |
| Q1 2022 | 2022-03-31 | $106,527 | $100,177 | +1577.59% |
| Q3 2021 | 2021-09-30 | $6,935 | $1,563 | +29.10% |
| Q2 2021 | 2021-06-30 | $6,834 | −$577 | −7.79% |
| Q1 2021 | 2021-03-31 | $6,350 | $5,511 | +656.85% |
| Q3 2020 | 2020-09-30 | $5,372 | $4,533 | +540.29% |
| Q2 2020 | 2020-06-30 | $7,411 | $7,411 | — |
| Q1 2020 | 2020-03-31 | $839 | $0 | 0.00% |
| Q3 2019 | 2019-09-30 | $839 | $0 | 0.00% |
| Q2 2019 | 2019-06-30 | $0 | −$839 | — |
| Q1 2019 | 2019-03-31 | $839 | −$9,476 | −91.87% |
| Q3 2018 | 2018-09-30 | $839 | $0 | 0.00% |
| Q2 2018 | 2018-06-30 | $839 | $0 | 0.00% |
| Q1 2018 | 2018-03-31 | $10,315 | $9,476 | +1129.44% |
| Q3 2017 | 2017-09-30 | $839 | $1 | +0.12% |
| Q2 2017 | 2017-06-30 | $839 | $0 | 0.00% |
| Q1 2017 | 2017-03-31 | $839 | $0 | 0.00% |
| Q3 2016 | 2016-09-30 | $838 | −$2 | −0.24% |
| Q2 2016 | 2016-06-30 | $839 | $839 | — |
| Q1 2016 | 2016-03-31 | $839 | $839 | — |
| Q3 2015 | 2015-09-30 | $840 | — | — |
| Q2 2015 | 2015-06-30 | $0 | — | — |
| Q1 2015 | 2015-03-31 | $0 | — | — |
Axim Biotechnologies depreciation and amortization trends
Over the last five fiscal years, Axim Biotechnologies's depreciation and amortization increased from $6,514 to $432,394, a change of $425,880. The latest reported quarter, Q2 2025, shows $108,130.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Axim Biotechnologies source filings ↗